TUBITAK Destekli Projelerden Çıkan Yayınlar Topluluğu
Published January 1, 2018 | Version v1
Journal article Open

Effect of metformin/irinotecan-loaded poly-lactic-co-glycolic acid nanoparticles on glioblastoma: in vitro and in vivo studies

Creators

  • 1. Ataturk Univ, Dept Pharmacol & Toxicol, Fac Vet Sci, TR-25240 Erzurum, Turkey
  • 2. Ataturk Univ, Dept Med Pharmacol, Fac Med, TR-25240 Erzurum, Turkey
  • 3. Ataturk Univ, Dept Pharmaceut Technol, Fac Pharm, TR-25240 Erzurum, Turkey
  • 4. Dept Biochem & Mol Biol, 91-95 Splaiul Independentei,Dist 5, Bucharest 050095, Romania
  • 5. D Mendeleev Univ Chem Technol Russia, Ctr Biomat, Miusskaya Sq 9, Moscow 125047, Russia
  • 6. Yuzuncu Yil Univ, Sch Med, Dept Med Biol, Van, Turkey
  • 7. Ataturk Univ, Dept Nephrol, Fac Med, TR-25240 Erzurum, Turkey
  • 8. Ataturk Univ, Dept Pathol, Fac Med, TR-25240 Erzurum, Turkey
  • 9. Seoul Natl Univ, Res Adm Team, Bundang Hosp, Gyeonggi, South Korea
  • 10. Chung Ang Univ, Dept Pharmacol, Coll Med, Seoul, South Korea

Description

Aim: The present study was designed to evaluate the effects of irinotecan hydrochloride (IRI)- or metformin hydrochloride (MET)-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles (NPs) for the treatment of glioblastoma multiforme using in vitro neuron and U-87 MG glioblastoma cell cultures and in vivo animal model. Methods: The cytotoxic and neurotoxic effects of pure drugs, blank NPs and MET- and IRI-loaded PLGA NPs were investigated in vitro (using methylthiazolyldiphenyl-tetrazolium bromide assay) and in vivo (using Cavalieri's principle for estimation of cancer volume). Results: 1 and 2 mM doses of MET and MET-loaded PLGA NPs, respectively, significantly reduced the volume of extracted cancer. Conclusion: Consequently, MET- and IRI-loaded PLGA NPs may be a promising approach for the treatment of glioblastoma multiforme.

Files

bib-5d5a33a9-e1ad-4525-bb1a-fedf07afc567.txt

Files (428 Bytes)

Name Size Download all
md5:540db0ecf3579c574aa8ed547db38951
428 Bytes Preview Download